Medical Cannabis Greece: EOF Fees and Exports

Medical cannabis Greece regulation is moving into a more export-focused phase in 2026. For consumers, that may sound distant from everyday CBD shopping. For operators, investors, pharmacies, and wellness businesses, it matters because the same framework shapes what can be produced, what can be exported, what can be sold domestically, and which products are likely to survive compliance pressure.

The headline is simple: Greece wants licensed medical cannabis production to become easier to use as an export platform, while keeping domestic medical use under strict pharmaceutical rules. EOF, the National Organisation for Medicines, remains central for medicines oversight. But export-only products are increasingly discussed as a separate lane, where the importing country’s rules, GMP expectations, and export documentation matter more than full Greek domestic circulation approval.

This guide explains the difference without legal jargon. It is written for adults, cannabis wellness readers, and business-minded operators who want a practical map of what changed, what is still uncertain, and why compliance is now the real competitive advantage.

Greece’s medical cannabis framework did not appear overnight. The production and licensing system is rooted in Law 4523/2018, which created a path for licensed cultivation, processing, possession, transport, and production of final medical cannabis products. Later measures and investment proposals have focused on making Greece more attractive as a regulated production base for Europe.

The current direction is not recreational legalisation. Adult-use cannabis remains illegal, and medical cannabis is controlled through licences and healthcare channels. Sources tracking European policy, including Business of Cannabis and Prohibition Partners, describe Greece as a medical-only market with growing export ambition rather than an open adult-use model.

The important distinction is domestic versus export. A product meant for Greek patients has to satisfy Greek pharmaceutical expectations. A product manufactured in Greece exclusively for export may be assessed primarily through the rules of the importing country, provided the Greek facility and export procedures are compliant. That sounds technical, but it is the difference between a slow domestic medicines pathway and a more flexible production-for-export model.

For background on Greece’s broader legal environment, read our Greece cannabis law 2026 guide and the recent hemp flower ban consumer guide.

✓ Key Takeaways

• ✓ Greece is positioning licensed medical cannabis as an export industry
• ✓ EOF remains central for pharmaceutical oversight
• ✓ Export-only products may avoid duplicate domestic circulation approval
• ✓ GMP, documentation, and importing-country rules still matter

EOF is Greece’s medicines authority. Its public medicines pages describe procedures, documentation, electronic submissions, and fees for human medicines through the EOF human medicines section. For medical cannabis, this matters because final products are treated as pharmaceutical products, not casual wellness goods.

For the Greek domestic market, EOF marketing authorisation is the serious gate. Product development, analytical methods, process validation, quality documentation, and stability data can become part of the file. That is why medical cannabis businesses talk about pharmaceutical compliance, not simply cultivation. A beautiful facility is not enough if the product dossier is weak.

For export-only lines, the emerging policy logic is different. Legal commentary from GMP Compliance explains that exported products are expected to follow the laws, regulations, and GMP/GDP guidelines of the importing country. In practice, Greece still cares about facility licensing and legal export controls, while the product registration burden may sit mainly with Germany, Switzerland, Poland, Australia, or whichever country receives the product.

That separation is why the phrase “EOF fees slashed” should be read carefully. The biggest saving may not always be a single visible price cut. It may be fewer duplicate filings, fewer domestic authorisation steps for export-only products, and less administrative friction when a product is not intended for Greek shelves.

The cleanest public information is that EOF publishes general human medicines fee categories, such as marketing authorisation, variations, renewals, and additional forms or strengths. These are not cannabis lifestyle fees. They are medicines-regulator fees, and they show the scale of paperwork involved when a product is placed through formal pharmaceutical channels.

The less clear part is cannabis-specific fee reduction detail in easily accessible English public pages. Search results and policy summaries point toward reduced burden for amendments, renewals, export-related authorisations, and export-only circulation requirements. But operators should not assume a blanket discount without checking the latest Greek-language ministerial decisions, Government Gazette entries, and EOF circulars.

There is also an export-only administrative concept in EOF systems. EOF’s repricing and market processes include declarations for products that are exclusively for export. That supports the idea that Greece recognises export-only status as a meaningful category, even if the exact cannabis fee schedule requires local legal review.

For readers comparing legal change with retail compliance, our cannabis retail licence Greece guide explains why location, documents, and regulator expectations now matter as much as product selection.

💡 Pro Tip

If you are evaluating a cannabis project in Greece, model three cost layers separately: facility licensing, domestic product authorisation, and export-only documentation. Mixing them creates bad budgets.

Domestic sale means Greek patients, Greek pharmacies, Greek medicine rules, and Greek marketing authorisation. Export means the product leaves Greece for a market whose regulator has its own expectations. That does not make export easy. It makes it differently difficult.

A Germany-facing product, for example, must satisfy German importer, pharmacy, quality, and documentation expectations. A Swiss shipment must satisfy Swiss rules. European cannabis operators also deal with narcotics controls, batch documentation, certificates, import permits, and quality audits. The European Medicines Agency is relevant for broader EU medicines context, even though national regulators still handle many cannabis-specific routes.

The commercial benefit is that Greek producers can potentially make finished products for countries with clearer demand while avoiding the delay of launching every product domestically. According to sector summaries, Greece recorded commercial export movement in 2024, and Business of Cannabis reported 49 kg exported to Germany in Q1 2025. That is not huge compared with mature import markets, but it proves the lane is real.

For consumers, the lesson is indirect but important: the brands that survive will be the ones built around quality systems. A cannabis market that moves toward pharmaceutical exports will reward testing, traceability, and documentation. That is also why we keep pushing readers toward lab reports, as explained in our cannabis lab results guide.

The first requirement is a realistic compliance file. Enterprise Greece’s licensing material for pharmaceutical cannabis installations outlines the importance of establishment approval, operational licensing, land and facility details, and competent ministry involvement. The official investment portal at Enterprise Greece is a useful starting point for the broader life sciences investment context.

Second, businesses need quality standards that match target markets. EU-GMP manufacturing, validated processes, batch records, stability data, packaging controls, and clean distribution agreements are not optional extras. The European Commission’s EudraLex Volume 4 is the reference point for EU GMP expectations.

Third, companies need export documentation discipline. Cannabis remains internationally controlled, so shipments are not ordinary herbal-commerce parcels. The International Narcotics Control Board framework sits behind national import and export controls for narcotic drugs. Import permits, quantities, recipient details, and deadlines have to match what authorities approve.

Fourth, do not overbuild around a single rule headline. Fee relief is useful, but weak supply contracts, unclear import-country authorisation, poor QA, or packaging that fails target-market requirements can still kill the project. In this sector, cheaper paperwork does not rescue sloppy operations.

📝 Important Note

This is a business and consumer education guide, not a licence application checklist. Anyone investing in a facility or export programme should use Greek regulatory counsel and verify current Government Gazette text.

Most adult consumers will not interact directly with EOF export filings. But the direction of regulation still affects what appears in shops, pharmacies, and online catalogues. When a market becomes more formal, low-quality products, unclear labels, and vague wellness promises become harder to defend.

That is why buyers should focus on practical quality signals: batch testing, clear cannabinoid percentages, THC compliance, ingredient transparency, and responsible claims. For wellness products, our CBD topicals safety guide shows how to separate ritual value from medical claims. For legal-risk awareness, our Greece cannabis penalties guide explains why personal assumptions about cannabis legality can be expensive.

Consumers should also understand the line between medical cannabis and CBD wellness products. Medical cannabis is not simply stronger CBD. It sits inside a healthcare and prescription context. CBD oils, topicals, and other wellness formats may be sold in different channels, but they still need responsible labelling and legal compliance.

A stricter, export-ready Greek cannabis sector may eventually improve trust. It can push better testing, cleaner manufacturing, and more professional retail behaviour. But it also means casual claims will be challenged. That is healthy for serious businesses and safer for adults who want evidence-based cannabis education.

⚠️ Disclaimer

This article is for informational purposes only and does not constitute medical or legal advice. The information provided about medical cannabis in Greece is current as of June 2026 but may change. Always consult qualified healthcare professionals for medical advice and qualified legal or regulatory advisers for licensing and export decisions. For our full disclaimer, visit cannastoreams.gr/disclaimer.